Danaher Co. (NYSE:DHR) Shares Sold by Eagle Bay Advisors LLC

Eagle Bay Advisors LLC trimmed its position in Danaher Co. (NYSE:DHR) by 20.8% in the 4th quarter, HoldingsChannel reports. The firm owned 544 shares of the conglomerate’s stock after selling 143 shares during the quarter. Eagle Bay Advisors LLC’s holdings in Danaher were worth $125,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC raised its position in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Danaher by 2.4% during the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after purchasing an additional 139,989 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Danaher by 3.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after purchasing an additional 148,251 shares during the period. Fisher Asset Management LLC boosted its holdings in Danaher by 2.6% in the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after purchasing an additional 116,299 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after buying an additional 535,254 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $239.83 on Tuesday. Danaher Co. has a twelve month low of $222.53 and a twelve month high of $281.70. The company has a market cap of $173.22 billion, a P/E ratio of 45.77, a P/E/G ratio of 4.32 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company’s 50-day moving average price is $235.52 and its 200-day moving average price is $253.65.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm posted $2.02 EPS. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio is presently 20.61%.

Analyst Ratings Changes

Several research analysts recently weighed in on DHR shares. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Royal Bank of Canada cut their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Stephens reissued an “overweight” rating and set a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a report on Friday, December 13th. Finally, Raymond James lowered their target price on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.